Literature DB >> 28722723

Untangling Fc and complement receptors to kill tumors.

Cees E van der Poel1, Michael C Carroll1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28722723     DOI： 10.1038/ni.3797

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  13 in total

1.  Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

Authors:  U Winkler; M Jensen; O Manzke; H Schulz; V Diehl; A Engert
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

2.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 3.  Building better monoclonal antibody-based therapeutics.

Authors:  George J Weiner
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

4.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 5.  How immunoglobulin G antibodies kill target cells: revisiting an old paradigm.

Authors:  Markus Biburger; Anja Lux; Falk Nimmerjahn
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

6.  Engineered antibodies with increased activity to recruit complement.

Authors:  E E Idusogie; P Y Wong; L G Presta; H Gazzano-Santoro; K Totpal; M Ultsch; M G Mulkerrin
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

Review 7.  Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.

Authors:  David J DiLillo; Jeffrey V Ravetch
Journal:  Cancer Immunol Res       Date:  2015-07       Impact factor: 11.151

8.  Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Authors:  David T Teachey; Susan R Rheingold; Shannon L Maude; Gerhard Zugmaier; David M Barrett; Alix E Seif; Kim E Nichols; Erica K Suppa; Michael Kalos; Robert A Berg; Julie C Fitzgerald; Richard Aplenc; Lia Gore; Stephan A Grupp
Journal:  Blood       Date:  2013-05-15       Impact factor: 22.113

Review 9.  Fcγ receptor pathways during active and passive immunization.

Authors:  Stylianos Bournazos; Jeffrey V Ravetch
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988

Review 10.  Mouse and human FcR effector functions.

Authors:  Pierre Bruhns; Friederike Jönsson
Journal:  Immunol Rev       Date:  2015-11       Impact factor: 12.988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.